In the United States, a patient was first treated with coronavirus infection with gimsilumab, a drug that can help reduce mortality from COVID-19 by reducing mortality from acute respiratory distress syndrome. Temple University Hospital reported this on its website.
Many patients infected with coronavirus infection experience an overactive immune response that leads to lung damage and acute respiratory distress syndrome (ARDS). The overall mortality rate of patients with ARDS is 41%, even despite the use of mechanical ventilation devices.
To combat ARDS, you can use gimsilumab – the human monoclonal body, which can reduce the level of lung hyper inflammation in people during the disease.
Gimsilumab has already been tested in several non-clinical studies, as well as two large clinical trials, including a four-week phase 1 study in healthy volunteers. In addition, it has already been tested in animals with coronavirus infection and patients with COVID-19 in China.
In the near future, scientists will begin a new study of the effect of the drug on 270 patients with COVID-19, severe lung damage and ARDS. If the therapy is successful, the WHO may include gimsilumab treatment in the list of mandatory procedures for complications of ARDS on the background of COVID-19.